Mazdutide, a Dual GLP-1/Glucagon Agonist, Achieves Substantial Weight Loss in Non-Diabetic Obese Adults

Obesity and type 2 diabetes are global health crises, often co-occurring and driving significant morbidity. Current weight loss and glycemic control therapies, while effective, often face limitations in efficacy or tolerability. Dual GLP-1 and glucagon receptor agonists like mazdutide offer a promising strategy by leveraging synergistic metabolic pathways to enhance satiety, reduce food intake, and improve glucose homeostasis beyond single-receptor agonism. This approach aims to address the complex pathophysiology of these conditions more comprehensively.

This meta-analysis systematically reviewed randomized controlled trials (RCTs) investigating Mazdutide in non-diabetic adults with overweight or obesity. Researchers searched Cochrane Library, PubMed, Google Scholar, and clinicaltrials.gov to identify relevant studies. The primary endpoints included changes in body weight and glycaemic parameters, alongside safety and tolerability profiles. The analysis aimed to synthesize evidence on Mazdutide's efficacy at various doses, including those up to 9 mg once-weekly, as explored in a separate trial in Chinese adults.

The meta-analysis confirmed that Mazdutide, a dual GLP-1 and glucagon receptor agonist, demonstrates significant efficacy for weight loss and glycaemic control in non-diabetic adults with obesity or overweight.

While specific quantitative data (e.g., percentage weight loss, HbA1c reduction, p-values) were not detailed in the abstract, the findings consistently indicated substantial improvements in both primary endpoints across the included randomized controlled trials. The safety profile of Mazdutide was also evaluated, suggesting a favorable tolerability, consistent with previous observations for GLP-1R agonists. Evidence from a separate trial specifically highlighted that Mazdutide 9 mg once-weekly provided substantial weight loss in Chinese adults with obesity, reinforcing its potential as a robust therapeutic option.